foundation-research-dkk-55.html
Novo Annual Report 2015
56 / 72
n ovo
nordisk
is a global healthcare company with more than 90 years of innovation and leadership in diabetes
care. this heritage has given the experience and capabilities that make it possible to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. the company?s key contribution is to discover and develop innovative biological medicines and make them available to patients throughout the world. this purpose is stated in the novo
nordisk way, which describes the ambitions and the values that characterise the company. the novo nordisk way also emphasises the importance of accounting for financial, social and environmental performance in accordance with the triple bottom line principle that is anchored in the company?s articles of association. financial performance in 2015, novo nordisk achieved its four long-term financial targets established in january 2013 and consequently, the board of directors has approved three updated long-term financial targets to guide novo nordisk?s performance. novo nordisk?s 2015 performance on operating profit and free cash flow slightly exceeded the outlook for the year provided in the latest guidance from october. sales increased by 8% measured in local currencies and by 22 % in danish kroner to 107.9 billion. operating profit increased by 43% in danish kroner to dkk 49.4 billion. in local currencies the growth was 21%. sales of diabetes and obesity care products increased by 22% measured in danish kroner and by 9% in local currencies to dkk 85,590 million. novo nordisk is the world leader in diabetes care and holds a global value market share of 28% compared to 27% at the same time last year. sales of biopharmaceutical products increased by 19% measured in danish kroner and by 6% in local currencies to dkk 22,337 million. r&d progress in march 2015, novo nordisk decided to resubmit new drug applications (nda) of tresiba ® and ryzodeg ® 70/30 in the us. the resubmission was based on the interim analysis of the cardiovascular outcomes trial for tresiba ® , devote. in order to preserve the integrity of the ongoing devote trial, only a small team within novo nordisk had access to the data and made the decision to resubmit the nda. novo nordisk management does not have access to the results of the interim analysis. the devote trial is expected to be completed in mid-2016 and the results are expected to be announced in the second half of 2016. the us food and drug administration (fda) approved tresiba ® and ryzodeg ® 70/30 for the treatment of diabetes in adults in september 2015. following the approval, tresiba ® was introduced to diabetes care specialists in the us during november 2015 and was launched broadly in january 2016. in august, novo nordisk decided to initiate a phase 3a programme with oral semaglutide; a once-daily oral formulation of the long-acting glp-1 analogue semaglutide. the decision followed the encouraging results of the proof- of-concept phase 2 trial announced in february 2015 and the subsequent consultations with regulatory authorities. in january 2016, novo nordisk submitted the marketing authorisation application (maa) to the european medicines agency (ema) for the approval of long-acting factor ix, nonacog beta pegol. the patient target: 40by20 as part of novo nordisk?s strategy for global access to diabetes care, the company has set a long-term target to reach 40 million people in 2020 with its diabetes care products, a doubling from the baseline number in 2010. the aim is to enable more people with diabetes to receive medical treatment. in 2014, novo nordisk provided medical treatments to an estimated 26.8 million patients with diabetes worldwide, compared with 24.4 million in 2014. for more information, please visit novo nordisk?s annual report 2015 at www.novonordisk.com/annualreport novo a/s 56 novo nordisk
novozymes-sales-2015-57.html
